Skip to main content

Table 2 Preclinical studies investigating the effect of CBD on neuropathic and nociceptive pain in vivo

From: Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research

Citation Animal Model Treatment(s) Treatment Effect
Neuropathic Pain
 De Gregorio et al., (2019) [51] Wistar rats SNI 5 mg·kg-1·d-1, s.c. 7 d CBD sig. decreased mechanical allodynia on Tx day 7.
 Casey et al., (2017) [29] C57BL/6 mice CCI 30 mg·kg-1, s.c. CBD sig. decreased mechanical allodynia 2 h, but not 0.5, 1, 4 or 6 h, post-Tx compared to baseline.
0.01, 0.1, 1, 10 or 100 mg·kg-1, s.c. CBD dose-dependently decreased mechanical and cold allodynia.
 King et al., (2017) [101] C57BL/6 mice CT (Paclitaxel) 0.625–20 mg·kg-1, i.p. 15 min prior to CT on days 1, 3, 5 and 7 1 and 20 mg·kg-1 CBD sig. attenuated the development of mechanical allodynia measured on Tx days 9 and 14, but not 21.
CT (Oxaliplatin) 1.25–10 mg·kg-1, i.p. 15 min prior to CT on days 1, 3, 5 and 7 1.25–10 mg·kg-1 CBD sig. attenuated the development of mechanical allodynia measured on Tx days 2, 4, 7 and 10.
CT (Vincristine) 1.25–10 mg·kg-1, i.p. 15 min prior to CT on days 1, 3, 5 and 7 CBD did not attenuate the development of CT-induced mechanical allodynia measured on Tx days 5, 10, 15 and 22.
 Harris et al., (2016) [78] C57BL/6 mice CT (Cisplatin) 2 mg·kg-1, i.p. CBD sig. decreased tactile allodynia 1 h post-Tx.
0.5, 1 or 2 mg·kg-1, i.p. 30 min prior to CT every second day for 12 d CBD did not attenuate the development of CT-induced tactile allodynia measured on Tx days 6, 10 and 12.
 Ward et al., (2014) [187] C57BL/6 mice CT (Paclitaxel) 2.5 or 5 mg·kg-1·d-1, i.p. 15 min prior to CT on days 1, 3, 5 and 7 2.5 and 5 mg·kg-1·d-1 CBD attenuated the development of CT-induced mechanical allodynia.
 Toth et al., (2010) [174] CD1 mice STZ Diabetes 0.1, 1 or 2 mg·kg-1·d-1, i.n. 3 months 1 and 2 mg·kg-1·d-1 CBD sig. attenuated the development of thermal and tactile hypersensitivity compared to 0.1 mg·kg-1·d-1 CBD.
2 mg·kg-1·d-1, i.n. 1 month CBD did not alleviate developed thermal or tactile hypersensitivity.
1, 10 or 20 mg·kg-1·d-1, i.p. 3 months 20 mg·kg-1·d-1 CBD sig. attenuated the development of thermal and tactile hypersensitivity compared to 1 mg·kg-1·d-1 CBD.
20 mg·kg-1·d-1, i.p. 1 month CBD did not alleviate developed thermal or tactile hypersensitivity.
 Costa et al., (2007) [41] Wistar rats CCI 2.5, 5, 10 or 20 mg·kg-1·d-1, oral 7 d 5, 10 and 20 mg·kg-1·d-1 CBD sig. decreased thermal and mechanical hyperalgesia on Tx day 7.
Nociceptive (Inflammatory) Pain
 Genaro et al., (2017) [70] Wistar rats Incision 0.3, 1, 3, 10 or 30 mg·kg-1, i.p. 3 mg·kg-1 CBD sig. decreased mechanical allodynia between 30- and 150-min post-Tx; 10 mg·kg-1 CBD sig. decreased mechanical allodynia 60 min post-Tx, only.
 Hammell et al., (2016) [75] Sprague-Dawley rats FCA 0.6, 3.1, 6.2 or 62.3 mg·kg-1·d-1, t.c. 4 d 6.2 and 62.3 mg·kg-1 CBD sig. decreased pain-related behaviour on Tx day 4 and thermal hyperalgesia on Tx days 2, 3 and 4.
 Costa et al., (2007) [41] Wistar rats FCA 20 mg·kg-1·d-1, oral 7 d CBD sig. decreased thermal and mechanical hyperalgesia on Tx day 7.
 Costa et al., (2004) [39] Wistar rats Carrageenan 5, 7.5, 10, 20 and 40 mg·kg-1, oral 5, 7.5, 10, 20 and 40 mg·kg-1·d-1 CBD sig. decreased thermal hyperalgesia 1–5 h post-Tx.
 Costa et al., (2004) [40] Wistar rats Carrageenan 10 mg·kg-1, oral CBD sig. decreased thermal hyperalgesia 1 h post-Tx.
  1. The ‘Treatment Effects’ described are in comparison to a vehicle condition, unless otherwise stated
  2. CBD Cannabidiol, CCI Chronic Constriction Injury, CT Chemotherapy, FCA Freund’s Complete Adjuvant, i.n. Intranasal, i.t. Intrathecal, s.c. Subcutaneous, SNI Spared Nerve Injury, STZ Streptozotocin, t.c. Transcutaneously, Tx Treatment